What's hot
View all perspectives
What's Hot
Psoriatic Arthritis Panel: EULAR 2025
Panelists Drs. Aurelie Najm, Eric Ruderman, Nelly Ziade, Jiha Lee and Jack Cush review highlights of PsA abstracts and sessions presented at the 2025 EULAR meeting in Barcelona, Spain.
Watch video →
Spondyloarthritis Panel: Eular 2025
Panelists: Drs. Peter Nash, Yuz Yusof, Antoni Chan, Adela Castro and Jack Cush.
Watch video →
Steroids, Not JAKi, Are the Real Infection Risk
Dr. David Liew reporting at EULAR 2025 in Barcelona, Spain.
Watch video →
Seronegative Arthritis Breakthroughs
Dr. Janet Pope discusses abstracts POS0015, "Zasocitinib (TAK-279) exhibits high levels of TYK2 inhibition and no inhibition of JAK 1/3 when compared with licensed TYK2 and JAK inhibitors" and POS0016, "Characterization of ORKA-002, a Novel Extended Half-life Monoclonal Antibody Targeting IL-17A/F for the Treatment of Psoriasis and Psoriatic Arthritis", presented at EULAR 2025 in Barcelona, Spain.
Watch video →
JAK Safety Update
Dr. Jonathan Kay offers his perspectives on abstracts POS0150, POS0151, and POS0157 presented at the 2025 EULAR meeting in Barcelona, Spain.
Watch video →
Who/When to Treat Clinically Suspect Arthralgia
Dr. Jack Cush discusses risk stratification in Clinically suspect arthralgia; referencing EULAR2025 abstracts OP0004 (ALTO study) and OP0325 (long term Followup of ARRIA)
Watch video →
Hidradenitis Suppurativa: What Lies Beneath?
Dr. David Liew reports on abstract POS1237 presented at the EULAR 2025 meeting in Barcelona, Spain.
Watch video →
The Value of Kidney Biopsy in Autoimmune Diseases
Dr. Andrea Fava shares his perspective from the EULAR 2025 meeting in Barcelona, Spain.
Watch video →
ICYMI: Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA
At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory rheumatoid arthritis (RA), a term now being used to describe a subset of patients who have failed to respond to five or more biologic or targeted synthetic DMARDs. This new classification, derived from recent multinational registry data, represents a significant step in refining our understanding and management of the most treatment-resistant forms of RA.
Read more →
Aurelie Najm AurelieRheumo
6 months 1 week ago
Ph 2 open label RCT TOFA in RA-ILD 52 wks
39pts 92% AE 8% 3 deaths FVC decline -69 ml
No diff between UIP, NSIP or antifibrotic
No control group
#POS0619 #EULAR2025 @RheumNow https://t.co/3lqEUfObG9
David Liew drdavidliew
6 months 1 week ago
What’s worse for infection in GCA: tail end steroid taper, or a JAK inhibitor?
This is exactly SELECT-GCA in the second 6mo. What happened?
upa skews better on serious infection, worse on HZ
JAKi might have infection risk, but not like steroids. OP0057 #EULAR2025 @RheumNow https://t.co/FigxviOW3e
Jiha Lee JihaRheum
6 months 1 week ago
Early PsA? Treat fast, treat hard.
The STAMP RCT showed that early secukinumab + MTX led to faster ACR50 and PASI90 responses vs standard care in a T2T strategy. By 12 months, outcomes were similar, but early SEC needed fewer escalations.
Abstract#OP0092
@RheumNow #EULAR2025 https://t.co/cAZTc9eN16
Adela Castro AdelaCastro222
6 months 1 week ago
Combination therapies in PsA not so far away:
-Case series of 22 patients from large PsA cohort.
-Combination therapy in PsA used when difficult to treat skin and msk involvement.
-Deucravacitinib was the agent mostly used in combination with bDMARDs.
-No major serious adverse https://t.co/YUyvuaJcsE
Jiha Lee JihaRheum
6 months 1 week ago
#OP0066 Danish registry study finds no increased risk of cancer recurrence with bDMARDs vs csDMARDs in RA patients with prior solid tumor in remission. IPTW-adjusted HR for any bDMARD: 0.92 (95% CI 0.38–2.21).
📉 TNFi, ,RTX also not associated with recurrence
@RheumNow #EULAR2025
Aurelie Najm AurelieRheumo
6 months 1 week ago
Case series of 22 PsA pts treats w/ combination bioDMARDs & JAKi,TYK2i or APR
IL17i + JAKi 10.5 PY = 1 mild infectious stomatitis
IL23i + JAKi 3.7 PY = no AE
IL-17i + TYK2i 8.5 PY = 2 mild upper respiratory infections
IL-23i + TYK2i 8.3 PY = 2 mild URIs, 1 folliculitis
TNFi + https://t.co/Qg9HIwuslJ
Adela Castro AdelaCastro222
6 months 1 week ago
Can IL-17F signalling be modulated by treatment with TNFi?
In PsA pts non responders to previous TNFi, there was increased expression of IL17F-related gene signature. Suggesting a potential mechanism for the consistent level of clinical response observed with BKZ.
Abstract https://t.co/D6fvp18UTz
Mrinalini Dey DrMiniDey
6 months 1 week ago
In #InflammatoryArthritis, baseline depression was linked to ↑ presenteeism & ↓ QoL at baseline + 3mo, but not absenteeism. Data from 9-country study provide further evidence that mental health is key to supporting work outcomes in RA, PsA & axSpA.
@RheumNow #EULAR2025 #OP0028
Md Yuzaiful Md Yusof Yuz6Yusof
6 months 1 week ago
#EULAR2025 Abstr#OP0074 Manufacturing time for CAR-T can be a hindrance. Preliminary study (N=10 #SLE patients) of CD19/BCMA dual-targeting CAR-T developed on the novel FasTCAR-T platform with next-day manufacturing, showed promising efficacy and safety signals @RheumNow https://t.co/bgF04qe9C7
Jiha Lee JihaRheum
6 months 1 week ago
Worried about cancer risk with ts/bDMARDs in RA?
Real-world data from over 4,600 patients says: don’t be. No increased risk of cancer (incl. NMSC) for JAKi, IL6i, CD20i, or CTLA4-A vs TNFi in long-term registry follow-up.
Abstract#OP0065
@RheumNow #EULAR2025
Antoni Chan MD (Prof) synovialjoints
6 months 1 week ago
Early intensive therapy in PsA.
STAMP RCT in early PsA:
•ACR50 at 3mo: 43% (early secukinumab) vs 22% (SoC)
•MDA at 3mo: 48% vs 25%
•PASI90 at 3mo: 60% vs 22%
By 12months: outcomes similar, but early secukinumab led to faster control and fewer therapy escalations. https://t.co/TKa5z24NQX
Mrinalini Dey DrMiniDey
6 months 1 week ago
Can lowering serum urate also lower CV risk? In >116k patients w/ #gout, achieving SU <360 µmol/L in 12m ↓ 5yr MACE risk (HR 0.89, pooled Δsurvival +1.4%). Greater effect in >65s. Gout management = CV prevention?
@RheumNow #EULAR2025 #OP0005 https://t.co/NRAerUBemN
Aurelie Najm AurelieRheumo
6 months 1 week ago
STAMP RCT early SEC vs. SoC 120pts
Retention 58% vs 30%
ACR 20, 50, 70 and MDA: better outcome at Month 3 but no difference at Month 6
Dactylitis no difference
Of note here SoC was a tight T2T strategy!
@RheumNow #OP0092 #EULAR2025 https://t.co/8zHs5CRFV5
Janet Pope Janetbirdope
6 months 1 week ago
What happens in pre-RA when you stop #abatacept after 1 yr Rx
At 6 yrs approx 60% on #Placebo
V
50% who initially got #ABA
Prolonged damped effect of development of #RA
NNT for 1 yr is ~10 with a range as low as 6
#EULAR2025 @RheumNow @eular_org
Abst#OP0004 https://t.co/1VOEaZ00Ia
Md Yuzaiful Md Yusof Yuz6Yusof
6 months 1 week ago
#EULAR2025 Abstr#OP0075 Interesting that even among #SLE patients, no single definition of “Lupus Under Control” reached at least 50% agreement. Live Poll with clinicians in the room further highlighted the discordant. More works are needed - to help tailor management @RheumNow https://t.co/WzkQkMD23i
Poster Hall